EC workshop on pharmaceutical/device borderline issues:
This article was originally published in Clinica
The European Commission is to hold a workshop on October 28 on the overlap between the pharmaceutical directives and other directives covering products that are on its borderline, including medical devices. This is a key issue for manufacturers of drug/device combination products, and products on the drug/device borderline who are still unclear to what extent the new pharmaceutical directive will have supremacy over medical device regulations.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.